AU4307396A - Kit for osteoporosis treatment cycle - Google Patents

Kit for osteoporosis treatment cycle Download PDF

Info

Publication number
AU4307396A
AU4307396A AU43073/96A AU4307396A AU4307396A AU 4307396 A AU4307396 A AU 4307396A AU 43073/96 A AU43073/96 A AU 43073/96A AU 4307396 A AU4307396 A AU 4307396A AU 4307396 A AU4307396 A AU 4307396A
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
tiludronic acid
calcium
kit
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU43073/96A
Other languages
English (en)
Inventor
Martine Gazard
Jacques Girard
Olivier Gros
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of AU4307396A publication Critical patent/AU4307396A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU43073/96A 1994-12-06 1995-12-05 Kit for osteoporosis treatment cycle Abandoned AU4307396A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9414630 1994-12-06
FR9414630A FR2727629A1 (fr) 1994-12-06 1994-12-06 Trousse pour cycle de traitement de l'osteoporose
PCT/FR1995/001596 WO1996017616A1 (fr) 1994-12-06 1995-12-05 Trousse pour cycle de traitement de l'osteoporose

Publications (1)

Publication Number Publication Date
AU4307396A true AU4307396A (en) 1996-06-26

Family

ID=9469504

Family Applications (1)

Application Number Title Priority Date Filing Date
AU43073/96A Abandoned AU4307396A (en) 1994-12-06 1995-12-05 Kit for osteoporosis treatment cycle

Country Status (20)

Country Link
EP (1) EP0797444A1 (fr)
JP (1) JPH10509729A (fr)
KR (1) KR980700083A (fr)
CN (1) CN1168634A (fr)
AR (1) AR002946A1 (fr)
AU (1) AU4307396A (fr)
BR (1) BR9509961A (fr)
CA (1) CA2207028A1 (fr)
CZ (1) CZ175397A3 (fr)
FI (1) FI972383A (fr)
FR (1) FR2727629A1 (fr)
HU (1) HUT77382A (fr)
IL (1) IL116168A0 (fr)
MA (1) MA23737A1 (fr)
NO (1) NO972558L (fr)
PL (1) PL320564A1 (fr)
SK (1) SK68597A3 (fr)
TR (1) TR199501530A1 (fr)
WO (1) WO1996017616A1 (fr)
ZA (1) ZA9510184B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
WO2003095029A1 (fr) 2002-05-10 2003-11-20 F. Hoffmann-La Roche Ag Acide bisphosphonique pour le traitement et la prevention de l'osteoporose
RU2315603C2 (ru) 2002-12-20 2008-01-27 Ф.Хоффманн-Ля Рош Аг Композиция с высокой дозой ибандроната

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE114473T1 (de) * 1984-04-30 1994-12-15 Procter & Gamble Ausrüstung für die verwendung bei der behandlung von osteoporose.
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DK0648120T3 (da) * 1992-06-30 1998-01-19 Procter & Gamble Pharma Anvendelse af phosphonater til behandling af osteoporose
FR2694558B1 (fr) * 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
ZA9510184B (en) 1996-06-11
WO1996017616A1 (fr) 1996-06-13
BR9509961A (pt) 1997-11-25
FI972383A0 (fi) 1997-06-05
FR2727629B1 (fr) 1997-02-28
SK68597A3 (en) 1997-11-05
EP0797444A1 (fr) 1997-10-01
NO972558L (no) 1997-08-05
PL320564A1 (en) 1997-10-13
JPH10509729A (ja) 1998-09-22
FI972383A (fi) 1997-06-05
IL116168A0 (en) 1996-01-31
FR2727629A1 (fr) 1996-06-07
AR002946A1 (es) 1998-05-27
MA23737A1 (fr) 1996-07-01
MX9704105A (es) 1997-09-30
CN1168634A (zh) 1997-12-24
TR199501530A1 (tr) 1996-10-21
NO972558D0 (no) 1997-06-05
CZ175397A3 (en) 1997-10-15
CA2207028A1 (fr) 1996-06-13
HUT77382A (hu) 1998-04-28
KR980700083A (ko) 1998-03-30

Similar Documents

Publication Publication Date Title
US20050026871A1 (en) Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin D derivative
US20050214388A1 (en) Multivitamin formulations containing controlled-release magnesium
US4861590A (en) Sustained release fluoride and calcium composition
CA2454200A1 (fr) Formes posologiques pour la liberation gastrique immediate d'un stimulateur de transport du calcium et la liberation gastrique retardee d'un bis-phosphonate
DE69837450T2 (de) Alendronate zur Behandlung von Osteoporose
KR100263284B1 (ko) 활성성분으로서의 디클로로메틸렌디포스폰산을 함유하는 생체 이용률이 개선된 정제
JP2006514695A (ja) ビタミンd誘導体の前用量投与によってアレンドロネート又は他のビスフォスフォネートの全体利用効率を高める方法
US20170157001A1 (en) Compositions Comprising Strontium and Uses Thereof in the Treatment or Prevention of Gingivitis, Periodontitis, Periodontitis as a Manifestation of Systemic Diseases, and Necrotizing Periodontal Diseases
US4859467A (en) Sustained release fluoride composition
US5013728A (en) Composition for treating osteoporosis and hormonal imbalance
CA2671727C (fr) Composition contenant un acide bisphosphonique combine a de la vitamine d
CZ219798A3 (cs) Prostředek pro prevenci a léčbu osteoporézy
AU4307396A (en) Kit for osteoporosis treatment cycle
EP0521057A1 (fr) Compositions pharmaceutiques contenant de l'ipriflavone, procede de preparation et utilisations pharmaceutiques de ces compositions.
US5286490A (en) Transdermal fluoride medication
MXPA97004105A (en) Set for use in a therapeutic treatment cycle of osteoporo
CA2219354A1 (fr) Prevention des pertes de dnets par l'administration d'alendronate ou de ses sels
HU211084B (en) Process for producing oral pharmaceutical composition of bone strengthening activity
EP0268868A2 (fr) Compositions pharmaceutiques pour le traitement des maladies gastro-intestinales

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted